Sexcord/ stromal ovarian tumors screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend routine screening for sexcord/ stromal ovarian tumors. According to the US Preventive Services Task Force(USPSTF) , screening for sexcord/ stromal ovarian tumors is not recommended in asymptomatic women | There is insufficient [[evidence]] to recommend routine [[screening]] for sexcord/ stromal ovarian tumors. According to the [[US Preventive Services Task Force|US Preventive Services Task Force(USPSTF)]] , [[screening]] for sexcord/ stromal ovarian tumors is not recommended in [[asymptomatic]] [[women]] | ||
==Screening== | ==Screening== | ||
*The US Preventive Services Task Force(USPSTF) recommends against screening for ovarian cancer in asymptomatic women<ref name="GrossmanCurry2018">{{cite journal|last1=Grossman|first1=David C.|last2=Curry|first2=Susan J.|last3=Owens|first3=Douglas K.|last4=Barry|first4=Michael J.|last5=Davidson|first5=Karina W.|last6=Doubeni|first6=Chyke A.|last7=Epling|first7=John W.|last8=Kemper|first8=Alex R.|last9=Krist|first9=Alex H.|last10=Kurth|first10=Ann E.|last11=Landefeld|first11=C. Seth|last12=Mangione|first12=Carol M.|last13=Phipps|first13=Maureen G.|last14=Silverstein|first14=Michael|last15=Simon|first15=Melissa A.|last16=Tseng|first16=Chien-Wen|title=Screening for Ovarian Cancer|journal=JAMA|volume=319|issue=6|year=2018|pages=588|issn=0098-7484|doi=10.1001/jama.2017.21926}}</ref><ref name="HendersonWebber2018">{{cite journal|last1=Henderson|first1=Jillian T.|last2=Webber|first2=Elizabeth M.|last3=Sawaya|first3=George F.|title=Screening for Ovarian Cancer|journal=JAMA|volume=319|issue=6|year=2018|pages=595|issn=0098-7484|doi=10.1001/jama.2017.21421}}</ref> | *The [[US Preventive Services Task Force]]([[USPSTF]]) recommends against [[screening]] for [[ovarian cancer]] in [[asymptomatic]] [[women]]<ref name="GrossmanCurry2018">{{cite journal|last1=Grossman|first1=David C.|last2=Curry|first2=Susan J.|last3=Owens|first3=Douglas K.|last4=Barry|first4=Michael J.|last5=Davidson|first5=Karina W.|last6=Doubeni|first6=Chyke A.|last7=Epling|first7=John W.|last8=Kemper|first8=Alex R.|last9=Krist|first9=Alex H.|last10=Kurth|first10=Ann E.|last11=Landefeld|first11=C. Seth|last12=Mangione|first12=Carol M.|last13=Phipps|first13=Maureen G.|last14=Silverstein|first14=Michael|last15=Simon|first15=Melissa A.|last16=Tseng|first16=Chien-Wen|title=Screening for Ovarian Cancer|journal=JAMA|volume=319|issue=6|year=2018|pages=588|issn=0098-7484|doi=10.1001/jama.2017.21926}}</ref><ref name="HendersonWebber2018">{{cite journal|last1=Henderson|first1=Jillian T.|last2=Webber|first2=Elizabeth M.|last3=Sawaya|first3=George F.|title=Screening for Ovarian Cancer|journal=JAMA|volume=319|issue=6|year=2018|pages=595|issn=0098-7484|doi=10.1001/jama.2017.21421}}</ref> | ||
*The USPSTF found that screening with either transvaginal ultrasound or testing for the serum tumor marker cancer antigen 125 (CA-125) or a combination of both does not reduce ovarian cancer mortality | *The [[USPSTF]] found that [[screening]] with either [[transvaginal ultrasound]] or [[testing]] for the [[serum]] [[tumor marker]] [[cancer]] [[antigen]] 125 ([[CA-125]]) or a combination of both does not reduce [[ovarian cancer]] [[mortality]] | ||
==References== | ==References== | ||
Latest revision as of 19:41, 2 May 2019
|
Sexcord/ stromal ovarian tumors Microchapters |
|
Differentiating Sexcord/ Stromal Ovarian Tumors from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Sexcord/ stromal ovarian tumors screening On the Web |
|
American Roentgen Ray Society Images of Sexcord/ stromal ovarian tumors screening |
|
Risk calculators and risk factors for Sexcord/ stromal ovarian tumors screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Maneesha Nandimandalam, M.B.B.S.[2]
Overview
There is insufficient evidence to recommend routine screening for sexcord/ stromal ovarian tumors. According to the US Preventive Services Task Force(USPSTF) , screening for sexcord/ stromal ovarian tumors is not recommended in asymptomatic women
Screening
- The US Preventive Services Task Force(USPSTF) recommends against screening for ovarian cancer in asymptomatic women[1][2]
- The USPSTF found that screening with either transvaginal ultrasound or testing for the serum tumor marker cancer antigen 125 (CA-125) or a combination of both does not reduce ovarian cancer mortality
References
- ↑ Grossman, David C.; Curry, Susan J.; Owens, Douglas K.; Barry, Michael J.; Davidson, Karina W.; Doubeni, Chyke A.; Epling, John W.; Kemper, Alex R.; Krist, Alex H.; Kurth, Ann E.; Landefeld, C. Seth; Mangione, Carol M.; Phipps, Maureen G.; Silverstein, Michael; Simon, Melissa A.; Tseng, Chien-Wen (2018). "Screening for Ovarian Cancer". JAMA. 319 (6): 588. doi:10.1001/jama.2017.21926. ISSN 0098-7484.
- ↑ Henderson, Jillian T.; Webber, Elizabeth M.; Sawaya, George F. (2018). "Screening for Ovarian Cancer". JAMA. 319 (6): 595. doi:10.1001/jama.2017.21421. ISSN 0098-7484.